|
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs.
We apply new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identify proprietary and related molecules for better patient treatment.
Recent Releases
May 9, 2012
ZIOPHARM Oncology to Present at the 11th Annual JMP Securities Research Conference
May 8, 2012
ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer
more »
Events
May 15, 2012
The 11th Annual JMP Securities Research Conference
May 9, 2012
The Deutsche Bank Securities 37th Annual Health Care Conference
more »
| 
